[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]

Abstract

EGFR tyrosine kinase inhibitors are currently included in the therapeutic armamentarium against advanced NSCLC. However, many questions on the use of anti-EGFR treatment in NSCLC still remain to be answered. Although several biological factors that may help identify those who are likely to respond to EGFR-targeted therapies have been reported, their clinical utility in routine practice remains to be determined. Moreover, the better way to combine EGFR targeted therapies with chemotherapy, new biological agents or loco-regional therapies at earlier stages of the disease is still under investigation. Clearly, the results of ongoing and future trials are required for an appropriate use of this new class of agents in NSCLC patients.